Memorial Hospital Research Laboratories
The Ying-Xian Pan Lab
Physician-scientist Ying-Xian Pan studies the mechanisms of opioid actions, providing the foundation of developing novel drugs for pain treatment.
The mu opioid receptors mediate the actions of morphine and most clinical analgesics, as well as drugs of abuse such as heroin. The goal of our research is to understand the mechanisms and functions of mu opioid receptor gene, OPRM1, gain insights into the pharmacological and physiological significance of the mechanisms and functions, and provide potential targets for developing novel drugs in control of pain and drug of abuse.
Huang XP, Che T, Mangano TJ, Le Rouzic V, Pan YX, Majumdar S, Cameron MD, Baumann MH, Pasternak GW and Roth BL. Fentanyl-related designer drugs W-18 and W-15 lack appreciable opioid activity in vitro and in vivo. JCI Insight. 2017 Nov 16;2(22). pii: 97222. doi: 10.1172/jci.insight.97222. [Epub ahead of print].
Baumann MH, Majumdar S, Le Rouzic V, Hunkele A, Uprety R, Huang XP, Xu J, Roth BL, Pan YX and Pasternak GW. Pharmacological characterization of novel synthetic opioids (NSO) found in the recreational drug marketplace. Neuropharmacology. 2017 Aug 12. pii: S0028-3908(17)30383-0. doi: 10.1016/j.neuropharm.2017.08.016. [Epub ahead of print].
Ying-Xian Pan, MD, PhD
- Physician-scientist Ying-Xian Pan studies the mechanisms of opioid actions, providing the foundation of developing novel drugs for pain treatment.
- Office Phone
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Ying-Xian Pan discloses the following relationships and financial interests:
Ownership / Equity Interests; Provision of Services (uncompensated)
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.